Enhanced Surveillance for Meningococcal Disease—United States, 2015–2019
PLOS One · 2025
DOI: 10.1371/journal.pone.0319940 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Amy B Rubis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Center…. Hauptthemen laut MEDLINE: Meningococcal Infections, Neisseria meningitidis, Population Surveillance. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).
Abstract (Originalsprache)
Background
High quality surveillance data are important to monitor U.S. epidemiology of meningococcal disease. Enhanced Meningococcal Disease Surveillance (EMDS) was established in 2015 to collect additional data and isolates from reported cases.
Methods
Epidemiologic information and isolates obtained through EMDS for meningococcal disease cases reported through the National Notifiable Diseases Surveillance System (NNDSS) during 2015 – 2019 were included in the analysis. Isolates were characterized by serogrouping and molecular typing using either Sanger sequencing or whole genome sequencing. Case fatality ratios (CFRs) were calculated using cases with known outcome as the denominator. Odds ratios (ORs) were calculated using logistic regression.
Results
A total of 1,806 meningococcal disease cases were reported during 2015 – 2019. The average annual incidence was 0.11 cases per 100,000 population. For key variables already collected through NNDSS, EMDS improved completeness over NNDSS by 21%-39% each year during 2015–2019. Completeness of key variables in EMDS improved over time by an average of 18%. Testing of isolates submitted through EMDS showed that serogroups B and C were predominant in all five years. For serogroup B, the most common clonal complex (CC) was CC32 in 2015 – 2017 and CC41/44 in 2018 – 2019; for serogroup C, CC11 was most common in 2015 – 2017 and CC103 in 2018 – 2019. The CFR was significantly lower for CC103 (6.7%) compared to other CCs (13.6%) (OR 0.44, 95% CI: 0.22–0.89).
Conclusions
U.S. incidence of meningococcal disease remained low during 2015 – 2019. Data and isolates obtained from EMDS supplement NNDSS and are critical to monitor U.S. meningococcal disease epidemiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States…
- Applied Science Research and Technology, Contractor assigned to Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for…
ORCID-Profile: Amy B Rubis, Daya Marasini, Brittney Thomas, Sara Eisen
Zitieren
APA
Rubis, A. B., Marasini, D., Howie, R., Wagle, B., Sharma, S., Thomas, B., Eisen, S., Shrestha, S., Marjuki, H., & McNamara, L. A. (2025). Enhanced Surveillance for Meningococcal Disease—United States, 2015–2019. PLOS One. https://doi.org/10.1371/journal.pone.0319940
Vancouver
Rubis AB, Marasini D, Howie R, Wagle B, Sharma S, Thomas B, et al. Enhanced Surveillance for Meningococcal Disease—United States, 2015–2019. PLOS One. 2025. doi:10.1371/journal.pone.0319940
BibTeX
@article{Rubis2025,
author = {Rubis, Amy B and Marasini, Daya and Howie, Rebecca and Wagle, Basanta and Sharma, Shalabh and Thomas, Brittney and Eisen, Sara and Shrestha, Sandip and Marjuki, Henju and McNamara, Lucy A},
title = {Enhanced Surveillance for Meningococcal Disease—United States, 2015–2019},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0319940}
}
EUVIMED